Last edition
News about "Biologics License Application "
AstraZeneca's Imfinzi Granted Priority Review by FDA for Early-Stage Gastric and GEJ Cancers
The US Food and Drug Administration (FDA) has accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) and granted Priority Review for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
Biologics License Application | 28/07/2025 | By Dineshwori
AbbVie Submits BLA to FDA for Teliso-V in Previously Treated Non-Small Cell Lung Cancer
AbbVie has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V).
Biologics License Application | 30/09/2024 | By Aishwarya | 289
Telix Completes TLX250-CDx BLA Submission for Kidney Cancer Imaging
Telix Pharmaceuticals has completed the submission of a Biologics License Application (BLA) to the United States (US) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET agent.
Biologics License Application | 03/06/2024 | By Aishwarya | 212
US FDA Grants Priority Review to Sarclisa for Treatment of Transplant-Ineligible NDMM
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab).
Biologics License Application | 28/05/2024 | By Aishwarya | 495
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy